| Date | Time | Source | Headline | Symbol | Company |
| 09/12/2019 | 7:30AM | PR Newswire (US) | GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial | LSE:0RU9 | Gt Biopharma Inc |
| 09/12/2019 | 7:30AM | PR Newswire (US) | GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial | LSE:0RU9 | Gt Biopharma Inc |
| 06/13/2019 | 7:30AM | PR Newswire (US) | GT Biopharma GTB-1550 | LSE:0RU9 | Gt Biopharma Inc |
| 06/13/2019 | 7:30AM | PR Newswire (US) | GT Biopharma GTB-1550 | LSE:0RU9 | Gt Biopharma Inc |
| 05/29/2019 | 7:30AM | PR Newswire (US) | GT Biopharma GTB-1550 PHASE I-II Results to be Published in Conjunction With 2019 ASCO Meeting May 31 - June 4 in Chicago | LSE:0RU9 | Gt Biopharma Inc |
| 05/29/2019 | 7:30AM | PR Newswire (US) | GT Biopharma GTB-1550 PHASE I-II Results to be Published in Conjunction With 2019 ASCO Meeting May 31 - June 4 in Chicago | LSE:0RU9 | Gt Biopharma Inc |
| 03/26/2019 | 7:30AM | PR Newswire (US) | GT Biopharma Announces Completion of Management Restructuring | LSE:0RU9 | Gt Biopharma Inc |
| 08/30/2018 | 8:00AM | PR Newswire (US) | GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Re... | LSE:0RU9 | Gt Biopharma Inc |
| 08/29/2018 | 7:45AM | PR Newswire (US) | GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Col... | LSE:0RU9 | Gt Biopharma Inc |
| 08/24/2018 | 8:00AM | PR Newswire (US) | GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance | LSE:0RU9 | Gt Biopharma Inc |
| 08/14/2018 | 8:00AM | PR Newswire (US) | GT Biopharma Announces GTBP CEO, Dr. Raymond Urbanski, to Make Presentation at the 2018 Wedbush PacGrow Healthcare Conference | LSE:0RU9 | Gt Biopharma Inc |
| 07/25/2018 | 8:00AM | PR Newswire (US) | GT Biopharma Announces the Addition of Dr. John N. Bonfiglio to its Board of Directors | LSE:0RU9 | Gt Biopharma Inc |
| 07/19/2018 | 8:00AM | PR Newswire (US) | GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination... | LSE:0RU9 | Gt Biopharma Inc |
| 06/05/2018 | 8:00AM | PR Newswire (US) | GT Biopharma Announces Voluntary Lock-Up Agreements With Insiders Covering Over 52% of Outstanding Shares | LSE:0RU9 | Gt Biopharma Inc |
| 05/14/2018 | 7:45AM | PR Newswire (US) | Gt Biopharma Announces Dr. Raymond W Urbanski Elevated to President and Chief Medical Officer of the Company | LSE:0RU9 | Gt Biopharma Inc |
| 04/26/2018 | 8:30AM | PR Newswire (US) | Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's Board of Directors | LSE:0RU9 | Gt Biopharma Inc |
| 04/24/2018 | 9:15AM | PR Newswire (US) | Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors | LSE:0RU9 | Gt Biopharma Inc |
| 03/29/2018 | 9:05AM | PR Newswire (US) | GT Biopharma Inc. Announces >50% Enrollment in Proof-Of-Concept Clinical Trial For Its Novel Treatment For Motion Sickness | LSE:0RU9 | Gt Biopharma Inc |
| 02/13/2018 | 7:45AM | PR Newswire (US) | GT Biopharma Announces Dr. Jeffrey Miller, Renowned NK Cell Cancer Specialist, Will Present at Cell Therapy Symposia | LSE:0RU9 | Gt Biopharma Inc |
| 01/24/2018 | 8:39AM | PR Newswire (US) | GT Biopharma, Inc. Issues Letter to Shareholders | LSE:0RU9 | Gt Biopharma Inc |
| 12/18/2017 | 10:27AM | PR Newswire (US) | GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing | LSE:0RU9 | Gt Biopharma Inc |